X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4015) 4015
Book Review (1525) 1525
Publication (326) 326
Book Chapter (24) 24
Conference Proceeding (12) 12
Magazine Article (4) 4
Presentation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3419) 3419
humans (2897) 2897
glucagon-like peptide-1 (2115) 2115
diabetes mellitus, type 2 - drug therapy (1560) 1560
male (1510) 1510
endocrinology & metabolism (1388) 1388
type 2 diabetes (1352) 1352
diabetes (1271) 1271
animals (1229) 1229
female (1159) 1159
hypoglycemic agents - therapeutic use (1155) 1155
glucose (960) 960
glucagon (880) 880
middle aged (871) 871
insulin (852) 852
pharmacology & pharmacy (750) 750
liraglutide (737) 737
glycemic control (671) 671
adult (658) 658
hypoglycemic agents - adverse effects (658) 658
peptides (648) 648
obesity (632) 632
treatment outcome (590) 590
blood glucose - metabolism (578) 578
glucagon-like peptide 1 (571) 571
glp-1 (565) 565
aged (549) 549
glucagon-like peptide 1 - analogs & derivatives (548) 548
exenatide (543) 543
diabetes mellitus (541) 541
hypoglycemic agents - administration & dosage (522) 522
diabetes mellitus, type 2 - blood (509) 509
care and treatment (471) 471
glucagon-like peptide 1 - therapeutic use (467) 467
double-blind (461) 461
dextrose (455) 455
blood glucose - drug effects (454) 454
analysis (451) 451
drug therapy (431) 431
metformin (431) 431
hypoglycemic agents (424) 424
research (419) 419
dipeptidyl-peptidase iv inhibitors - therapeutic use (410) 410
internal medicine (407) 407
mice (403) 403
hypoglycemic agents - pharmacology (402) 402
risk factors (393) 393
abridged index medicus (389) 389
diabetes therapy (382) 382
glucagon-like peptide-1 receptor (380) 380
peptides - therapeutic use (377) 377
rats (374) 374
beta-cell function (372) 372
clinical trials (368) 368
type-2 diabetes-mellitus (366) 366
medicine & public health (364) 364
insulin resistance (360) 360
glucagon-like peptide 1 - metabolism (353) 353
health aspects (353) 353
diabetes mellitus, type 2 - metabolism (341) 341
double-blind method (335) 335
physiological aspects (333) 333
safety (331) 331
hyperglycemia (321) 321
body weight (320) 320
insulin - blood (314) 314
drug therapy, combination (313) 313
insulin - metabolism (294) 294
medicine, general & internal (288) 288
glucagon-like peptide-1 receptor - agonists (286) 286
venoms - therapeutic use (284) 284
receptors, glucagon - agonists (275) 275
type 2 diabetes mellitus (272) 272
open-label (270) 270
secretion (269) 269
rodents (267) 267
glucagon-like peptide 1 - blood (266) 266
metabolism (263) 263
hypoglycemia (258) 258
efficacy (257) 257
glucagon-like peptide 1 - adverse effects (257) 257
glycated hemoglobin a - metabolism (256) 256
review (256) 256
diabetes mellitus, type 2 - complications (255) 255
glucose metabolism (247) 247
sitagliptin (243) 243
incretins - therapeutic use (241) 241
glucagon-like peptide 1 - administration & dosage (230) 230
food-intake (227) 227
dipeptidyl peptidase-4 inhibitor (226) 226
nutrition & dietetics (223) 223
obesity - drug therapy (220) 220
peptides - administration & dosage (220) 220
digestive, oral, and skin physiology (218) 218
incretin (218) 218
insulin secretion (217) 217
drug administration schedule (215) 215
peptides - adverse effects (212) 212
insulin-secretion (210) 210
peptides - pharmacology (209) 209
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3940) 3940
German (29) 29
Spanish (18) 18
Japanese (10) 10
French (8) 8
Danish (4) 4
Korean (4) 4
Portuguese (3) 3
Russian (3) 3
Chinese (2) 2
Czech (2) 2
Hungarian (2) 2
Italian (2) 2
Dutch (1) 1
Norwegian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2159 - 2167
OBJECTIVE To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The... 
GLYCEMIC CONTROL | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | ANALOG LIRAGLUTIDE | OPEN-LABEL | LY2189265 | TREATED PATIENTS | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Thiazolidinediones - administration & dosage | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Venoms - adverse effects | Hypoglycemia - drug therapy | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Safety and security measures | Dosage and administration | Metformin | Comparative analysis | Exenatide | Clinical trials | Hemoglobin | Diabetes | Product safety | Drug dosages | Placebo effect | Index Medicus
Journal Article
Diabetes Care, ISSN 0149-5992, 10/2014, Volume 37, Issue 10, pp. 2763 - 2773
OBJECTIVE: Mealtime insulin is commonly added to manage hyperglycemia in type 2 diabetes when basal insulin is insufficient. However, this complex regimen is... 
CONTROLLED-TRIAL | GLYCEMIC CONTROL | ORAL-THERAPY | COMBINATION THERAPY | PARALLEL-GROUP | EXENATIDE | ENDOCRINOLOGY & METABOLISM | OPEN-LABEL | TREATED PATIENTS | TREATMENT SATISFACTION | GETGOAL-L | Glycated Hemoglobin A - analysis | Hypoglycemia - epidemiology | Humans | Middle Aged | Body Weight - drug effects | Male | Hyperglycemia - drug therapy | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Hypoglycemia - chemically induced | Meals | Receptors, Glucagon - agonists | Drug Administration Schedule | Venoms - adverse effects | Insulin - administration & dosage | Treatment Outcome | Insulin Lispro - administration & dosage | Blood Glucose - drug effects | Insulin, Long-Acting - adverse effects | Diabetes Mellitus, Type 2 - blood | Insulin, Long-Acting - administration & dosage | Glucagon-Like Peptide-1 Receptor | Insulin Glargine | Insulin Lispro - adverse effects | Quality of Life | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Dosage and administration | Hypoglycemia | Insulin | Weight gain | Health aspects | Risk factors | Diabetes | Glucose | Medical treatment | Quality of life | Index Medicus
Journal Article
Gastroenterology, ISSN 0016-5085, 2011, Volume 141, Issue 1, pp. 150 - 156
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 19, pp. 1834 - 1844
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2149 - 2158
OBJECTIVE To compare the efficacy and safety of two doses of once-weekly dulaglutide, a glucagon-like peptide 1 receptor agonist, to sitagliptin in... 
METFORMIN | GLYCEMIC CONTROL | PLACEBO | GLP-1 | GLUCAGON-LIKE PEPTIDE-1 | RECEPTOR AGONISTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | ANALOG LIRAGLUTIDE | OPEN-LABEL | INHIBITOR SITAGLIPTIN | Glycated Hemoglobin A - analysis | Triazoles - administration & dosage | Triazoles - adverse effects | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Immunoglobulin Fc Fragments - administration & dosage | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Double-Blind Method | Treatment Outcome | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Pyrazines - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Sitagliptin | Care and treatment | Dosage and administration | Safety and security measures | Comparative analysis | Clinical trials | Hemoglobin | Glycosylation | Diabetes | Product safety | Placebo effect | Index Medicus | Psychosocial Research | Nutrition | Education | Clinical Care
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2168 - 2176
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9951, pp. 1349 - 1357
Summary Background Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | EFFICACY | PHYSICAL-ACTIVITIES | SAFETY | PARALLEL-GROUP | EXENATIDE | ANALOG LIRAGLUTIDE | GATEKEEPING PROCEDURES | DAILY LIVING QUESTIONNAIRE | PEPTIDE-1 RECEPTOR AGONISTS | Metformin - therapeutic use | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Hypoglycemic Agents - administration & dosage | Fasting - blood | Female | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Treatment Outcome | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Analysis of Variance | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Type 2 diabetes | Usage | Research | Comparative analysis | Drug therapy | Clinical trials | Enzymes | Blood pressure | Diabetes | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 06/2013, Volume 123, Issue 6, pp. 2730 - 2736
Journal Article